LRRK2 and Parkinson disease: Potential neuroprotective PD therapies and clinical trials are now targeting specific PD subtypes based on genetic markers causing or increasing the disease risk, such as therapies targeting LRRK2, GBA1 and alpha-synuclein (Sardi et al., 2018).